In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway

British Journal of Cancer

Volumn 96, Issue 3, 2007, Pages 485-491

  Pils, D ^a   Pinter, A ^a   Reibenwein, J ^a   Alfanz, A ^a   Horak, P ^a   Schmid, B C ^a   Hefler, L ^a   Horvat, R ^a   Reinthaller, A ^a   Zeillinger, R ^a   Krainer, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CXCR4; HER2 neu; Immunohistochemistry; Ovarian cancer; SDF 1; Tissue microarray

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CHEMOKINES, CXC; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 33846786653     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603581     Document Type: Article

References (23)

1. Almofti A, Uchida D, Begum NM, Tomizuka Y, Iga H, Yoshida H, Sato M (2004) The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int J Oncol 25: 65-71
2. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43
3. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR (1997) The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 94: 1925-1930
4. Jemal A, Murray T, Ward E, Samuels A (2005) Cancer statistics, 2005. Ca-A Cancer J Clin 55: 10-30
5. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR (2005) Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97: 1840-1847
6. Kato M, Kitayama J, Kazama S, Nagawa H (2003) Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5: R144-R150
7. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23: 2744-2753
8. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R (2005) Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11: 2561-2567
9. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459-469
10. Naora H, Montell DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355-366
11. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM (2003) The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167: 1676-1686
12. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103-2111
13. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104: 550-557
14. Salmaggi A, Gelati M, Pollo B, Marras C, Silvani A, Balestrini MR, Eoli M, Fariselli L, Broggi G, Boiardi A (2005) CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neurooncol 74: 287-293
15. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M (2005) The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97: 275-283
16. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11: 1835-1841
17. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De lG-S (2006) Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32: 180-190
18. Shibuta K, Mori M, Shimoda K, Inoue H, Mitra P, Barnard GF (2002) Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation. Jpn J Cancer Res 93: 789-797
19. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
20. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE (1999) Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 5: 2485-2490
21. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le CT, Soria JC (2004) Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15: 613-617
22. Tan DS, Agarwal R, Kaye SB (2006) Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7: 925-934
23. Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, Hoskins WJ (1995) Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 57: 61-65